Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Respir Med ; 188: 106619, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34555702

RESUMEN

BACKGROUND: Invasive fungal infections (IFI) are increasing in prevalence in recent years. In the last few months, the rise of COVID-19 patients has generated a new escalation in patients presenting opportunistic mycoses, mainly by Aspergillus. Candida infections are not being reported yet. OBJECTIVES: We aimed to determine the prevalence of systemic candidiasis in patients admitted to ICUs due to severe pneumonia secondary to SARS-CoV-2 infection and the existence of possible associated risk factors that led these patients to develop candidiasis. PATIENTS/METHODS: We designed a study including patients with a confirmed diagnosis of COVID-19. RESULTS: The prevalence of systemic candidiasis was 14.4%, and the main isolated species were C. albicans and C. parapsilosis. All patients that were tested positive for Candida spp. stayed longer in the ICU in comparison to patients who tested negative. Patients with candidiasis had higher MuLBSTA score and mortality rates and a worse radiological involvement. In our study, Candida spp. isolates were found in patients that were submitted to: tocilizumab, tocilizumab plus systemic steroids, interferon type 1ß and Lopinavir-Ritonavir. CONCLUSIONS: Results suggested a high prevalence of systemic candidiasis in severe COVID-19-associated pneumonia patients. Patients with Candidiasis had the worst clinical outcomes. Treatment with tocilizumab could potentialize the risk to develop systemic candidiasis.


Asunto(s)
COVID-19/complicaciones , Candidiasis/epidemiología , Coinfección/epidemiología , Neumonía/epidemiología , Anciano , COVID-19/diagnóstico , Candida albicans , Candida parapsilosis , Candidiasis/complicaciones , Candidiasis/diagnóstico , Coinfección/diagnóstico , Cuidados Críticos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neumonía/microbiología , Neumonía/virología , Prevalencia , Estudios Prospectivos , Factores de Riesgo
2.
Mycoses ; 64(2): 144-151, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33217071

RESUMEN

BACKGROUND: As the global coronavirus pandemic (COVID-19) spreads across the world, new clinical challenges emerge in the hospital landscape. Among these challenges, the increased risk of coinfections is a major threat to the patients. Although still in a low number, due to the short time of the pandemic, studies that identified a significant number of hospitalised patients with COVID-19 who developed secondary fungal infections that led to serious complications and even death have been published. OBJECTIVES: In this scenario, we aim to determine the prevalence of invasive fungal infections (IFIs) and describe possible associated risk factors in patients admitted due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. PATIENTS/METHODS: We designed an open prospective observational study at the Rey Juan Carlos University Hospital (Mostoles, Spain), during the period from February 1 to April 30, 2020. RESULTS: In this article, we reported seven patients with COVID-19-associated pulmonary aspergillosis (CAPA) who had a poor prognosis. Severely ill patients represent a high-risk group; therefore, we must actively investigate the possibility of aspergillosis in all of these patients. Larger cohort studies are needed to unravel the role of COVID-19 immunosuppressive therapy as a risk factor for aspergillosis. CONCLUSIONS: As the pandemic continues to spread across the world, further reports are needed to assess the frequency of emergent and highly resistant reemergent fungal infections during severe COVID-19. These coinfections are leading a significant number of patients with COVID-19 to death due to complications following the primary viral disease.


Asunto(s)
COVID-19/complicaciones , Aspergilosis Pulmonar Invasiva/etiología , Infecciones Oportunistas/microbiología , Adulto , Anciano , Aspergillus/genética , Aspergillus/aislamiento & purificación , Aspergillus/fisiología , COVID-19/virología , Femenino , Hospitalización , Humanos , Instituciones de Cuidados Intermedios/estadística & datos numéricos , Aspergilosis Pulmonar Invasiva/microbiología , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/etiología , Prevalencia , Estudios Prospectivos , SARS-CoV-2/fisiología , España
3.
Respir Med ; 144: 74-81, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30366588

RESUMEN

BACKGROUND: Evidence is needed to determine the role of telehealth (TH) in COPD management. METHODS: PROMETE II was a multicentre, randomized, 12-month trial. Severe COPD patients in stable condition were randomized to a specific monitoring protocol with TH or routine clinical practice (RCP). The primary objective was to reduce the number of COPD exacerbations leading to ER visits/hospital admissions between groups. RESULTS: Overall, 237 COPD patients were screened, and 229 (96.6%) were randomized to TH (n = 115) or RCP (n = 114), with age of 71 ±â€¯8 years and 80% were men. Overall, 169 completed the full follow-up period. There were no statistical differences at one year between groups in the proportion of participants who had a COPD exacerbation (60% in TH vs. 53.5% in RCP; p = 0.321). There was, however, a marked but non-significant trend towards a shorter duration of hospitalization and days in ICU in the TH group (18.9 ±â€¯16.0 and 6.0 ±â€¯4.6 days) compared to the RCP group (22.4 ±â€¯19.5 and 13.3 ±â€¯11.1 days). The number of all-cause deaths was comparable between groups (12 in TH vs. 13 in RCP) as was total resource utilization cost (7912€ in TH vs. 8918€ in RCP). Telehealth was evaluated highly positively by patients and doctors. CONCLUSIONS: Remote patient management did not reduce COPD-related ER visits or hospital admissions compared to RCP within 12 months.


Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/terapia , Telemedicina , Anciano , Anciano de 80 o más Años , Atención Ambulatoria/estadística & datos numéricos , Causas de Muerte , Progresión de la Enfermedad , Servicio de Urgencia en Hospital/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Costos de la Atención en Salud , Recursos en Salud/economía , Recursos en Salud/estadística & datos numéricos , Humanos , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Aceptación de la Atención de Salud , Enfermedad Pulmonar Obstructiva Crónica/economía , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Índice de Severidad de la Enfermedad , Telemedicina/economía , Telemedicina/estadística & datos numéricos , Factores de Tiempo
4.
Med. clín (Ed. impr.) ; 151(4): 136-140, ago. 2018. tab
Artículo en Español | IBECS | ID: ibc-173864

RESUMEN

Fundamento y objetivos: Determinar la utilidad de la estratificación pronóstica empírica para identificar a pacientes con tromboembolia de pulmón (TEP) aguda sintomática y bajo riesgo de complicaciones precoces. Pacientes y métodos: Este estudio incluyó a un total de 154 pacientes consecutivos diagnosticados de TEP aguda sintomática en un hospital universitario terciario. Comparamos la capacidad pronóstica de la escala clínica Pulmonary Embolism Severity Index (PESI), la escala PESI simplificada (PESIs) y la evaluación empírica de: 1) 2médicos adjuntos (uno con y otro sin experiencia en el manejo de pacientes con TEP); 2) un residente de cuarto año de Neumología; 3) un residente de tercer año de Neumología, y 4) un residente de segundo año de Neumología. El evento primario de mal pronóstico fue la mortalidad por todas las causas durante el primer mes después del diagnóstico de la TEP. Resultados: Durante los primeros 30 días después del diagnóstico de la TEP se produjo el fallecimiento de 13 pacientes (8,4%; intervalo confianza [IC] del 95%, 4,1-12,8%). Hubo una tendencia (no estadísticamente significativa) a clasificar más pacientes de bajo riesgo mediante la escala PESI o la evaluación empírica que con la escala PESIs (36,4, 31,3 y 28,6%, respectivamente). No se produjo ningún evento en el grupo de pacientes de bajo riesgo según la escala PESIs. Se detectó una mayor eficacia pronóstica de la estratificación empírica conforme mayor fue la experiencia clínica de los evaluadores (84,6 vs. 92,3%; p = 0,049). Conclusiones: La escala PESIs es la herramienta más eficaz para identificar pacientes con TEP aguda sintomática y bajo riesgo de muerte por todas las causas durante el primer mes de seguimiento. La evaluación pronóstica empírica realizada por médicos experimentados no es menos eficaz que la realizada mediante escalas estandarizadas


Background and objective: To determine the accuracy of clinical gestalt to identify patients with acute symptomatic pulmonary embolism (PE) at low-risk for short-term complications. Patients and methods: This study included a total of 154 consecutive patients diagnosed with acute symptomatic PE in a tertiary university hospital. We compared the prognostic accuracy of the Pulmonary Embolism Severity Index (PESI), the simplified PESI (sPESI), and clinical gestalt of 1) 2senior physicians (one with and one without experience in the management of patients with PE), 2) a fourth-year resident of Pneumology, 3) a third-year resident of Pneumology, and 4) a second-year resident of Pneumology. The primary outcome was all-cause mortality during the first month after the diagnosis of PE. Results: Thirty-day all-cause mortality was 8.4% (13/154; 8.4%; 95% confidence interval [CI], 4.1-12.8%). The PESI and clinical gestalt classified more patients as low-risk, compared to the sPESI (36.4%, 31.3% y 28.6%, respectively). There were no deaths in the sPESI low-risk category (negative predictive value 100%). Prognostic accuracy increased with increasing experience (84.6 vs. 92.3%; P=.049). Conclusions: The sPESI showed the best accuracy at correctly identifying low-risk patients with acute symptomatic PE. Clinical gestalt is not inferior to standardized clinical prediction rules to prognosticate patients with acute PE


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Embolia Pulmonar/mortalidad , Pesos y Medidas , Pronóstico , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/complicaciones , Enoxaparina/administración & dosificación , Vitamina K/antagonistas & inhibidores
6.
Med Clin (Barc) ; 151(4): 136-140, 2018 08 22.
Artículo en Inglés, Español | MEDLINE | ID: mdl-29276010

RESUMEN

BACKGROUND AND OBJECTIVE: To determine the accuracy of clinical gestalt to identify patients with acute symptomatic pulmonary embolism (PE) at low-risk for short-term complications. PATIENTS AND METHODS: This study included a total of 154 consecutive patients diagnosed with acute symptomatic PE in a tertiary university hospital. We compared the prognostic accuracy of the Pulmonary Embolism Severity Index (PESI), the simplified PESI (sPESI), and clinical gestalt of 1) 2senior physicians (one with and one without experience in the management of patients with PE), 2) a fourth-year resident of Pneumology, 3) a third-year resident of Pneumology, and 4) a second-year resident of Pneumology. The primary outcome was all-cause mortality during the first month after the diagnosis of PE. RESULTS: Thirty-day all-cause mortality was 8.4% (13/154; 8.4%; 95% confidence interval [CI], 4.1-12.8%). The PESI and clinical gestalt classified more patients as low-risk, compared to the sPESI (36.4%, 31.3% y 28.6%, respectively). There were no deaths in the sPESI low-risk category (negative predictive value 100%). Prognostic accuracy increased with increasing experience (84.6 vs. 92.3%; P=.049). CONCLUSIONS: The sPESI showed the best accuracy at correctly identifying low-risk patients with acute symptomatic PE. Clinical gestalt is not inferior to standardized clinical prediction rules to prognosticate patients with acute PE.


Asunto(s)
Competencia Clínica , Embolia Pulmonar/mortalidad , Índice de Severidad de la Enfermedad , Enfermedad Aguda , Anciano , Causas de Muerte , Intervalos de Confianza , Femenino , Humanos , Internado y Residencia , Masculino , Pronóstico , Embolia Pulmonar/diagnóstico por imagen , Embolia Pulmonar/terapia , Neumología , Medición de Riesgo , Evaluación de Síntomas , Factores de Tiempo
8.
Eur Respir J ; 41(2): 354-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22743671

RESUMEN

Although the Pulmonary Embolism Severity Index (PESI) accurately identifies 35% of patients with acute pulmonary embolism (PE) as being low risk, some patients deemed high risk by the PESI on admission might be treated safely in the outpatient environment. This retrospective cohort study included a total of 304 consecutive patients with acute PE, classified at the time of hospital admission into PESI class III. The PESI was recalculated 48 h after admission (PESI(48)) and each patient reclassified into the corresponding risk category. The primary outcome of the study was all-cause mortality between day 2 and day 30 after PE diagnosis. 26 (8.5%) patients (95% CI 5.4-11.7%) died between day 2 and day 30 after PE diagnosis. Investigators reclassified 83 (27.3%) patients (95% CI 22.3-32.3%) as low risk (classes I and II) at 48 h. 30-day mortality in these patients was 1.2% (95% CI 0-3.5%) as opposed to 11.3% (95% CI 7.1-15.5%) in those who remained high risk. The net improvement in reclassification was estimated at 54% (p<0.001). In a cohort of intermediate-risk patients with acute PE, calculation of the PESI(48) allows identification of those patients at very low risk of dying during the first month of follow-up.


Asunto(s)
Embolia Pulmonar/clasificación , Embolia Pulmonar/diagnóstico , Neumología/normas , Anciano , Atención Ambulatoria , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Admisión del Paciente , Pronóstico , Estudios Prospectivos , Embolia Pulmonar/mortalidad , Neumología/métodos , Sistema de Registros , Medición de Riesgo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
9.
Arch. bronconeumol. (Ed. impr.) ; 46(12): 628-633, dic. 2010. graf, tab
Artículo en Español | IBECS | ID: ibc-90231

RESUMEN

Introducción y objetivosEvaluar la incidencia de hipertensión pulmonar tromboembólica crónica (HPTEC) sintomática y asintomática en una cohorte de pacientes con tromboembolia de pulmón (TEP), y las variables predictoras de su aparición.MétodosEstudio prospectivo de cohorte de 110 pacientes consecutivos diagnosticados de TEP en un hospital universitario terciario, y seguidos durante 24 meses. Todos los pacientes fueron sometidos a una ecocardiografía transtorácica (ETT) al final del seguimiento. En los pacientes sintomáticos con una presión sistólica pulmonar estimada (PAP) ≥40mmHg se realizó un cateterismo cardiaco derecho para confirmar la HPTEC. En los pacientes asintomáticos se repitió la ETT a los 6 meses de la primera y, si la PAP se mantenía por encima de 40mmHg, se indicó un cateterismo cardiaco.ResultadosSe confirmó HPTEC en 10 pacientes de la serie (9,1%; intervalo de confianza [IC] 95%, 3,7 a 14,5%). Todos los pacientes con HPTEC presentaron síntomas sugestivos de la enfermedad. La edad (riesgo relativo [RR] ajustado 1,2 por cada año; IC 95%, 1,0 a 1,3; p=0,03) y el antecedente de TEP (RR 5,7; IC 95%, 1,5 a 22,0; p=0,01) se asociaron de forma estadísticamente significativa al diagnóstico de HPTEC.ConclusionesLa incidencia de HPTEC es más frecuente de lo descrito previamente en la literatura. La asociación entre las recurrencias tromboembólicas y la HPTEC sugiere la necesidad de optimizar la duración y la intensidad del tratamiento anticoagulante en los pacientes con TEP. No se detectaron episodios de HPTEC en pacientes asintomáticos(AU)


Introduction and objectivesTo assess the incidence of long-term symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension (CTEPH) in a cohort of patients with acute symptomatic pulmonary embolism (PE), and the potential risk factors for its diagnosis.MethodsWe conducted a prospective, long-term, follow-up study in 110 consecutive patients with an acute episode of pulmonary embolism (PE). All patients underwent transthoracic echocardiography (TTE) two years after the diagnosis of PE was made. If systolic pulmonary artery pressure exceeded 40mmHg and there was evidence of residual PE either by ventilation-perfusion or CT scan, patients underwent right heart catheterisation to confirm the diagnosis. In asymptomatic patients, right heart catheterisation was performed if a repeated TTE still demonstrated persistent pulmonary hypertension six months after the first.ResultsCTEPH was diagnosed in 10 (6 patients during follow-up, and 4 at the end of the study) of the 110 patients (9.1%; 95% confidence interval [CI], 3.7 to 14.5%). All patients showed symptoms related to the disease according to a structured questionnaire. In the multivariate regression analysis, only concomitant age (relative risk [RR] 1.2 per age; 95% CI, 1.0 to 1.3; P=0.03) and previous PE (RR 5.7; IC 95%, 1.5 a 22.0; P=0.01) were independent predictors of CTEPH.ConclusionsCTEPH cumulative incidence appears to be higher than previously reported. All patients had symptoms related to the disease(AU)


Asunto(s)
Humanos , Hipertensión Pulmonar/complicaciones , Embolia Pulmonar/complicaciones , Ecocardiografía/métodos , Cateterismo Cardíaco/métodos , Anticoagulantes/uso terapéutico , Estudios Prospectivos , Encuestas Epidemiológicas
10.
Arch Bronconeumol ; 46(12): 628-33, 2010 Dec.
Artículo en Español | MEDLINE | ID: mdl-20926172

RESUMEN

INTRODUCTION AND OBJECTIVES: To assess the incidence of long-term symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension (CTEPH) in a cohort of patients with acute symptomatic pulmonary embolism (PE), and the potential risk factors for its diagnosis. METHODS: We conducted a prospective, long-term, follow-up study in 110 consecutive patients with an acute episode of pulmonary embolism (PE). All patients underwent transthoracic echocardiography (TTE) two years after the diagnosis of PE was made. If systolic pulmonary artery pressure exceeded 40 mm Hg and there was evidence of residual PE either by ventilation-perfusion or CT scan, patients underwent right heart catheterisation to confirm the diagnosis. In asymptomatic patients, right heart catheterisation was performed if a repeated TTE still demonstrated persistent pulmonary hypertension six months after the first. RESULTS: CTEPH was diagnosed in 10 (6 patients during follow-up, and 4 at the end of the study) of the 110 patients (9.1%; 95% confidence interval [CI], 3.7 to 14.5%). All patients showed symptoms related to the disease according to a structured questionnaire. In the multivariate regression analysis, only concomitant age (relative risk [RR] 1.2 per age; 95% CI, 1.0 to 1.3; P=0.03) and previous PE (RR 5.7; IC 95%, 1.5 a 22.0; P=0.01) were independent predictors of CTEPH. CONCLUSIONS: CTEPH cumulative incidence appears to be higher than previously reported. All patients had symptoms related to the disease.


Asunto(s)
Hipertensión Pulmonar/epidemiología , Embolia Pulmonar/epidemiología , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Femenino , Estudios de Seguimiento , Humanos , Hipertensión Pulmonar/complicaciones , Incidencia , Masculino , Estudios Prospectivos , Embolia Pulmonar/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...